Skip to NavigationSkip to content

AstraZeneca lupus drug makes comeback to meet main goal at Phase 3

Published on 29/08/19 at 10:37am

AstraZeneca has lifted the curtain on new Phase 3 data for anifrolumab, noting that the drug met its primary endpoint in the treatment of systemic lupus erythematosus (SLE).

The new findings revealed that patients taking anifrolumab, combined with standard of care, achieved a statistically-significant and clinically-meaningful reduction in disease activity versus placebo plus standard of care, as measured by British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) after 52 weeks of treatment.

These latest data represent a turning point from the failure of the therapy last year to meet its primary goal in a late stage trial.

“As clinicians we need new medicines for this complex and difficult-to-treat disease,” commented Professor Eric F Morand of Monash University, and Principal Investigator on the TULIP 2 trial. “These exciting results from the TULIP 2 trial demonstrate that, by targeting the type I interferon receptor, anifrolumab reduced disease activity in patients with systemic lupus erythematosus.”

LSE is an autoimmune condition in which the body’s immune system attacks its own healthy tissues, leading to organ damage as well as fatigue, rashes, pain, fever and swelling of joints; those living with the disease are also more susceptible to death from infection and cardiovascular disease.

In the last six decades, there has only been one new therapy approved for the disease.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches